Healthcare Services

The Malignant Pleural Effusion Market Is Advancing With Support From Rising Cases Of Lung Cancer Driving The Growth Of The Market Due To Increasing Treatment Demand

June 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Growth In Market Size Of The Malignant Pleural Effusion Market During 2026–2030?

The malignant pleural effusion market size has experienced significant growth in recent years. Its expansion is projected to move from $4.73 billion in 2025 to $5.05 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.8%. Historically, this growth can be ascribed to several key factors, including the rising incidence of metastatic cancers, the limited availability of curative treatment options, the necessity for repeated thoracentesis for symptom control, the growth of hospital-based cancer care, and the gradual implementation of pleurodesis techniques.

The malignant pleural effusion market size is projected to experience robust growth in the upcoming years. It is predicted to expand to $6.52 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.6%. This anticipated growth during the forecast period can be attributed to several factors including the increasing global prevalence of cancer, continuous advancements in pleural catheter technologies, a heightened emphasis on outpatient and home-based care options, improved precision in diagnostic imaging, and a rising demand for treatments centered on enhancing quality of life. Significant trends identified for this period encompass a greater utilization of indwelling pleural catheters for sustained management, a growing preference for less invasive pleural interventions, the broader integration of systemic cancer therapies in malignant pleural effusion management, an increased focus on approaches for symptom relief and palliative care, and the expansion of diagnostic and therapeutic procedures guided by imaging.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22047&type=smp

Which Drivers Are Advancing The Malignant Pleural Effusion Market Growth?

The increasing incidence of lung cancer is anticipated to propel the growth of the malignant pleural effusion market. Lung cancer is a condition marked by the uncontrolled multiplication of abnormal cells in the lungs, forming tumors that disrupt normal lung function. The rise in lung cancer cases is linked to smoking and tobacco consumption, as extended exposure to detrimental chemicals in cigarettes harms lung tissues, initiates genetic mutations, and encourages the unregulated growth of cancerous cells, substantially heightening the likelihood of developing the disease. Malignant pleural effusion indicates advanced lung cancer progression by enabling tumor spread within the pleural cavity, resulting in deteriorated respiratory function and a less favorable prognosis. For instance, in January 2023, the American Cancer Society Facts and Figures, a US-based professional organizations company, reported estimated new lung and bronchus cancer cases were 236,740 in 2022 and 238,340 in 2023, while estimated deaths stood at 130,180 in 2022 and 127,070 in 2023. Consequently, the rising cases of lung cancer are driving the expansion of the malignant pleural effusion market.

What Are The Major Segment Categories Within The Malignant Pleural Effusion Market?

The malignant pleural effusion market covered in this report is segmented –

1) By Treatment: Systemic Therapy, Therapeutic Thoracentesis, Thoracic Drainage And Pleurodesis, Indwelling Pleural Catheter

2) By Diagnosis: Pleural Fluid Cytology, Immunohistochemical Tests, Imaging Tests, Pleural Thoracentosis, Pleuroscopy, Pleural Biopsy

3) By End Users: Hospitals, Ambulatory Clinics, Other End Users

Subsegments:

1) By Systemic Therapy: Chemotherapy, Targeted Therapy, Immunotherapy

2) By Therapeutic Thoracentesis: Single-Time Thoracentesis, Repeated Thoracentesis

3) By Thoracic Drainage And Pleurodesis: Chemical Pleurodesis, Mechanical Pleurodesis

4) By Indwelling Pleural Catheter: Tunneled Pleural Catheter, Non-Tunneled Pleural Catheter

What Trends Are Affecting The Growth Of The Malignant Pleural Effusion Market?

Leading companies operating in the malignant pleural effusion market are concentrating on developing innovative products, such as fully-implantable automatic fluid-shunt devices, to enhance patient comfort and decrease hospital visits. A fully-implantable automatic fluid-shunt device is a medical apparatus surgically placed within the body that automatically drains excess pleural fluid from the lungs into the abdomen or another region, thereby helping to relieve breathlessness symptoms, reduce the need for repeated hospital procedures, and improve the patient’s quality of life. For instance, in October 2023, Pleural Dynamics, a US-based medical device company, launched the ACES Automatic Continuous Effusion Shunt System. This device is composed of a resilient flexible pump chamber implanted under the skin between the ribs, with one catheter in the pleural space and another in the peritoneal space. As the patient breathes, the internal pump extension is compressed and decompressed between adjacent ribs, propelling fluid from the pleural cavity to the abdomen where it is reabsorbed; the system also permits manual activation through an external compression extension. Key features include a fully implantable design, no external drainage tubing or suction bottles, a breathing-powered automatic pumping function, minimal hospital stay for implantation, and continuous symptom relief from recurrent effusions.

Which Key Players Are Active In The Malignant Pleural Effusion Market?

Major companies operating in the malignant pleural effusion market are Becton Dickinson and Company, Cook Medical LLC, Merit Medical Systems Inc, Argon Medical Devices Inc, B Braun SE, Medtronic plc, Smiths Medical, Teleflex Incorporated, Cardinal Health Inc, Getinge AB, AngioDynamics Inc, Rocket Medical plc, Redax SpA, Atrium Medical Corporation, PolyMedicure Ltd, Troge Medical GmbH, Vygon SA, ICU Medical Inc, ConvaTec Group plc, Baxter International Inc

Access The Complete Malignant Pleural Effusion Market Report:

https://www.thebusinessresearchcompany.com/report/malignant-pleural-effusion-global-market-report

Which Region Is The Dominant Market In The Malignant Pleural Effusion Market?

North America was the largest region in the malignant pleural effusion market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant pleural effusion market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Malignant Pleural Effusion Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=22047&type=smp

Browse Through More Reports Similar to the Global Malignant Pleural Effusion Market 2026, By The Business Research Company

Acoustic Neuroma Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/acoustic-neuroma-global-market-report

Paraganglioma Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/paraganglioma-global-market-report

Adult Malignant Glioma Therapeutics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795